重组人血管内皮抑制素联合TP化疗方案治疗非小细胞肺癌患者的效果  

Effects of recombinant human endostatin combined with TP chemotherapy in treatment of patients with non-small cell lung cancer

作　　者：张娜[1] 周敬奎 ZHANG Na;ZHOU Jingkui(Department of Respiratory and Critical Care Medicin of the Second Affiliated Hospital of Luohe Medical College,Luohe 462000 Henan,China)

机构地区：[1]漯河医学高等专科学校第二附属医院呼吸与危重症医学科,河南漯河462000

出　　处：《中国民康医学》2025年第5期47-49,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察重组人血管内皮抑制素联合TP化疗方案治疗非小细胞肺癌(NSCLC)患者的效果。方法:回顾性分析2020年9月至2023年2月该院收治的94例NSCLC患者的临床资料,按照治疗方法不同将其分为对照组和观察组各47例。对照组采用TP化疗方案(紫杉醇+顺铂)治疗,观察组在对照组基础上联合重组人血管内皮抑制素治疗。比较两组临床疗效,治疗前后血清学指标[热休克蛋白90α(HSP90α)、血管内皮生长因子(VEGF)、高迁移率族蛋白A2(HMGA2)、血管生成素-2(Ang-2)]水平、健康状态[Karnofsky功能状态量表(KPS)]评分,以及不良反应发生率。结果:观察组疾病控制率(DCR)为91.49%(43/47),高于对照组的70.21%(33/47),差异有统计学意义(P<0.05);治疗后,两组VEGF、HSP90α、Ang-2、HMGA2水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组KPS评分均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组白细胞减少、恶心呕吐、肝肾功能异常等不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:重组人血管内皮抑制素联合TP化疗方案治疗NSCLC患者可提高DCR和健康状态评分,降低血清学指标水平,效果优于单纯TP化疗方案治疗。Objective:To observe effects of recombinant human endostatin combined with TP chemotherapy in treatment of patients with non-small cell lung cancer(NSCLC).Methods:The clinical data of 94 patients with NSCLC admitted to this hospital from September 2020 to February 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,47 cases in each group.The control group was treated with TP chemotherapy(Paclitaxel+Cisplatin),while the observation group was treated with recombinant human endostatin on the basis of that of the control group.The clinical efficacy,the levels of serological indexes [heat shock protein 90α(HSP90α),vascular endothelial growth factor(VEGF),high mobility group protein A2(HMGA2),angiopoietin-2(Ang-2)],the health status [Karnofsky performance status(KPS)] score before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disease control rate(DCR) of the observation group was 91.49%(43/47),which was higher than 70.21%(33/47) of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of VEGF,HSP90α,Ang-2 and HMGA2 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the KPS scores of the two groups were higher than those before the treatment,that in the observation group was higher than that in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions such as leukopenia,nausea and vomiting,liver and kidney dysfunction between the two groups(P>0.05).Conclusions:Recombinant human endostatin combined with TP chemotherapy in the treatment of the NSCLC patients can improve the DCR and the health status scores,and reduce the levels of serological indexes.Moreover,it

关 键 词：重组人血管内皮抑制素 TP化疗方案 非小细胞肺癌 健康状态 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]